|
|
Article: Endovasc Phase II Positive; Firm Explores Next Options.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
West Coast Editor
Having reported in June that preliminary data were positive, Endovasc Inc. said full results of the Phase II trial of Liprostin for peripheral vascular disease (PVD) are encouraging as well.
The news was enough to boost Montgomery, Texas-based Endovasc's stock (OTC BB:EVSC) up 29.6 percent to close at 14 cents Thursday. Endovasc said it is exploring "a number of financial strategies" for getting Liprostin into Phase III trials.
"Until now, we haven't had anything hard-core that suggests the drug is active," said Diane Dottavio, president and CEO of Endovasc.
"We would welcome any kind of licensing or co-development ...